ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS TRISPECIFIC ANTIBODY, ISB 2001

The U.S. Food and Drug Administration grants orphan drug designation to ISB 2001 for the treatment of multiple myeloma NEW YORK, July 7, 2023 /PRNewswire/ — Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.